The study aims to compare the quality of life of the patients with solid cancer before and after treatment with fluoxetine and placebo. In this randomized, double-blind clinical trial, 150 patients with solid cancer referring to the hematology and oncology department of Imam Khomeini Hospital of Ardabil, Iran will enter the study. The main inclusion criteria include being over 15 years of age and lack of known psychological disorders.
Exclusion criteria include lack of interest for participation, use of medications with depressive symptoms, being diagnosed with other psychiatric disorders. Patients will be given questionnaires containing personal information with two questions: 1) In the last month, have you had any feelings of disappointment or depression? 2) In the last month, have you had any feelings of lack of interest in doing your jobs? The answers will be ranked based on the scale of 0 to 4. Patients with scores of 5 or more will be entered into the next phase of the study. After the random selection of patients, Fluoxetine 20 mg and placebo will be prescribed orally to the intervention group and the control group, respectively, for 12 weeks. If side effects emerge, the medicine will be stopped and the patient will be excluded from the study. Before and after the intervention, the patients will answer a questionnaire of general health and quality of life. Based on the answers, the general health and quality of life status of the patients before and after the intervention will be compared.